[go: up one dir, main page]

WO2007023382A3 - Pyrimidine amino pyrazole compounds, potent kinase inhibitors - Google Patents

Pyrimidine amino pyrazole compounds, potent kinase inhibitors Download PDF

Info

Publication number
WO2007023382A3
WO2007023382A3 PCT/IB2006/002344 IB2006002344W WO2007023382A3 WO 2007023382 A3 WO2007023382 A3 WO 2007023382A3 IB 2006002344 W IB2006002344 W IB 2006002344W WO 2007023382 A3 WO2007023382 A3 WO 2007023382A3
Authority
WO
WIPO (PCT)
Prior art keywords
kinase inhibitors
pyrazole compounds
amino pyrazole
potent kinase
pyrimidine amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002344
Other languages
French (fr)
Other versions
WO2007023382A2 (en
Inventor
Chuangxing Guo
Mary Catherine Johnson
Haitao Li
Joseph Timothy Marakovits
Indrawan James Mcalpine
Liming Dong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2007023382A2 publication Critical patent/WO2007023382A2/en
Publication of WO2007023382A3 publication Critical patent/WO2007023382A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pyrrole pyrazole compounds of formula I, compositions including these compounds, and methods of their use are provided. Ring A is optionally substituted. The ring formed by Z1, Z2, Z3, Z4 and the two intervening carbons is also optionally substituted. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
PCT/IB2006/002344 2005-08-25 2006-08-17 Pyrimidine amino pyrazole compounds, potent kinase inhibitors Ceased WO2007023382A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71164105P 2005-08-25 2005-08-25
US60/711,641 2005-08-25
US80414406P 2006-06-07 2006-06-07
US60/804,144 2006-06-07

Publications (2)

Publication Number Publication Date
WO2007023382A2 WO2007023382A2 (en) 2007-03-01
WO2007023382A3 true WO2007023382A3 (en) 2007-04-26

Family

ID=37529269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002344 Ceased WO2007023382A2 (en) 2005-08-25 2006-08-17 Pyrimidine amino pyrazole compounds, potent kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2007023382A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372850B2 (en) 2006-11-02 2013-02-12 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
US8383633B2 (en) 2007-05-02 2013-02-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8410133B2 (en) 2007-03-09 2013-04-02 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US8426425B2 (en) 2006-12-19 2013-04-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8455507B2 (en) 2007-04-13 2013-06-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8518953B2 (en) 2007-03-09 2013-08-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8524720B2 (en) 2000-09-15 2013-09-03 Vertex Pharmaceuticals Incorporated Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors
US8557833B2 (en) 2005-11-03 2013-10-15 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8598361B2 (en) 2007-07-31 2013-12-03 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof
US8633210B2 (en) 2000-09-15 2014-01-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
US8653088B2 (en) 2003-02-06 2014-02-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US8664219B2 (en) 2007-03-09 2014-03-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8785444B2 (en) 2007-05-02 2014-07-22 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654792A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CN101687852A (en) * 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 Thiazoles and pyrazoles useful as kinase inhibitors
JP5567481B2 (en) 2007-10-09 2014-08-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridine derivatives useful as glucokinase activators
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
JP2011525533A (en) * 2008-06-24 2011-09-22 コデクシス， インコーポレイテッド A biocatalytic method for the preparation of substantially stereoisomerically pure fused bicyclic proline compounds
US20110053916A1 (en) 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
KR101790255B1 (en) 2009-12-23 2017-10-26 다케다 야쿠힌 고교 가부시키가이샤 Fused heteroaromatic pyrrolidinones as syk inhibitors
MX2012014158A (en) 2010-06-04 2013-02-07 Hoffmann La Roche Aminopyrimidine derivatives as lrrk2 modulators.
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
ES2653967T3 (en) 2010-11-10 2018-02-09 Genentech, Inc. Pyrazole aminopyrimidine derivatives as modulators of LRRK2
EP2640369A1 (en) 2010-11-17 2013-09-25 F.Hoffmann-La Roche Ag Methods of treating tumors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
CN104168898A (en) 2012-03-16 2014-11-26 霍夫曼-拉罗奇有限公司 Methods of treating melanoma with PAK1 inhibitors
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2013152717A1 (en) 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 Fused pyrimidine compound, and preparation method, intermediate, composition， and uses thereof
US9499519B2 (en) 2012-12-26 2016-11-22 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
HUE049801T2 (en) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopyrazole kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EP3070084A1 (en) * 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
EA038890B1 (en) 2015-11-02 2021-11-03 Блюпринт Медсинс Корпорейшн Inhibitors of ret
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
AR107912A1 (en) 2016-03-17 2018-06-28 Blueprint Medicines Corp RET INHIBITORS
WO2018017983A1 (en) * 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3781168A4 (en) * 2018-04-16 2022-10-05 The Regents of the University of California PAK4 INHIBITORS AND METHODS OF USE
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS
MX2022008627A (en) 2020-01-13 2022-11-08 Verge Analytics Inc PYRAZOLO-SUBSTITUTED PYRIMIDINES AND USES THEREOF.
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
KR20230017234A (en) 2020-05-29 2023-02-03 블루프린트 메디신즈 코포레이션 Solid forms of pralcetinib
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022107919A1 (en) * 2020-11-19 2022-05-27 주식회사 보로노이 N-containing heteroaryl derivative, and pharmaceutical composition for preventing or treating protein kinase-related diseases comprising same as active ingredient
WO2024206628A1 (en) * 2023-03-30 2024-10-03 Nalo Therapeutics Modulators of myc family proto-oncogene protein
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002022602A2 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
WO2004096810A1 (en) * 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2005040159A1 (en) * 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
WO2006067614A2 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006100461A1 (en) * 2005-03-23 2006-09-28 Astrazeneca Ab 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
WO2006118231A1 (en) * 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002022602A2 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2004096810A1 (en) * 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
WO2005040159A1 (en) * 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
WO2006067614A2 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006100461A1 (en) * 2005-03-23 2006-09-28 Astrazeneca Ab 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
WO2006118231A1 (en) * 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633210B2 (en) 2000-09-15 2014-01-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
US8524720B2 (en) 2000-09-15 2013-09-03 Vertex Pharmaceuticals Incorporated Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors
US8653088B2 (en) 2003-02-06 2014-02-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US8557833B2 (en) 2005-11-03 2013-10-15 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8637511B2 (en) 2005-11-03 2014-01-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8372850B2 (en) 2006-11-02 2013-02-12 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
US8426425B2 (en) 2006-12-19 2013-04-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8518953B2 (en) 2007-03-09 2013-08-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8410133B2 (en) 2007-03-09 2013-04-02 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US8664219B2 (en) 2007-03-09 2014-03-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8735593B2 (en) 2007-03-09 2014-05-27 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US8455507B2 (en) 2007-04-13 2013-06-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8383633B2 (en) 2007-05-02 2013-02-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8785444B2 (en) 2007-05-02 2014-07-22 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
US8598361B2 (en) 2007-07-31 2013-12-03 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof

Also Published As

Publication number Publication date
WO2007023382A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
WO2007023382A3 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007072153A8 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2009158571A8 (en) Heteroaryl compounds and uses thereof
WO2007000339A8 (en) Bicyclic derivatives as p38 kinase inhibitors
WO2005021536A3 (en) Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
MY152283A (en) Polo-like kinase inhibitirs
EP1864665A4 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2007117995A3 (en) Kinase inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2007146124A3 (en) Deuterated tadalafil derivatives
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
WO2005076990A3 (en) Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
WO2006065820A3 (en) Pyrimidine inhibitors of erk protein kinase and uses therof
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2008054956A3 (en) Kinase inhibitors
PT1877364E (en) Phenylacetylene derivatives having mglur5 receptor affinity
TW200638930A (en) Acetylene derivatives
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2009129401A8 (en) Kinase inhibitors
WO2006110173A3 (en) Novel compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06795353

Country of ref document: EP

Kind code of ref document: A2